Related Experiment Video
Updated: Jul 15, 2026
06:11
Monitoring Blood Glucose in Mouse Offspring After Intracytoplasmic Sperm Injection
Published on: May 17, 2024
Pregnancy failure and heritable thrombophilia.
1Department of Clinical Epidemiology, and Vascular Medicine Unit, Leiden University Medical Center, Leiden, The Netherlands. s.middeldorp@lumc.nl
Seminars in Hematology
|April 17, 2007
Summary
Heritable thrombophilia increases pregnancy failure risk, including miscarriage and preeclampsia. Current treatments lack strong evidence; new trials are needed before intervention.
Area of Science:
- Reproductive Medicine
- Hematology
- Genetics
Background:
- Heritable thrombophilia is linked to adverse pregnancy outcomes like miscarriage, preeclampsia, and intrauterine growth retardation.
- The underlying mechanisms may involve trophoblast differentiation, not just hypercoagulability.
- Recurrent pregnancy loss, particularly early miscarriage, is a significant concern in affected women.
Purpose of the Study:
- To review the role of heritable thrombophilia in pregnancy failure.
- To focus on the epidemiology, etiology, and therapeutic implications for recurrent miscarriage.
- To assess the current evidence for interventions in women with heritable thrombophilia and pregnancy loss.
Main Methods:
- Literature review focusing on heritable thrombophilia and pregnancy outcomes.
- Analysis of epidemiological data and etiological factors.
- Evaluation of existing therapeutic options and clinical trial evidence.
Main Results:
- Heritable thrombophilia is a significant risk factor for various pregnancy failures.
- Pathogenesis likely extends beyond hypercoagulability to affect placental development.
- Evidence supporting current treatments like aspirin and heparin for recurrent pregnancy loss in this context is limited due to inadequate trial comparators.
Conclusions:
- Women with heritable thrombophilia face an elevated risk of pregnancy failure.
- Further randomized controlled trials with placebo or no-treatment arms are crucial.
- Results from ongoing trials are necessary to guide safe and effective interventions for pregnancy loss in these patients.
Related Concept Videos
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
01:24Disorders of Hemostasis
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
01:49Probability Laws
Overview
01:07Teratogenicity
The ability of a drug to produce structural deformations and functional abnormalities in the developing embryo or the fetus is called teratogenicity, and the drug producing this effect is known as a teratogen. Teratogenic effects include stillbirth, miscarriage, intrauterine growth restriction, and neurocognitive delay. A teratogen may affect the embryo at different stages of development, which is important in determining the type and extent of the damage. During blastocyst formation, the early...
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
01:30Venous Thrombosis I: Introduction
Venous thrombosis, the most common disorder of the veins, involves the formation of a thrombus or blood clot associated with vein inflammation. It can be classified as either superficial vein thrombosis or deep vein thrombosis.Superficial Vein Thrombosis: This involves the formation of a thrombus in a superficial vein, usually the greater or lesser saphenous vein. Though less severe than deep vein thrombosis (DVT), SVT can lead to complications if untreated.Deep Vein Thrombosis (DVT): This...